Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.56, $1.80 worse than the analyst estimate of $3.36. Revenue for the quarter came in at $74.1 million versus the consensus estimate of $116.95 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Isabella Bank added to Russell 2000 index after Nasdaq listing
• MotorK names Roy Toren to board as Helen Protopapas resigns